Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    0.00 (0.00%)
Bid:
0.00
Ask:
540.00
Spread: 35.00 (6.931%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

25 Jul 2024 07:00

RNS Number : 7319X
Tate & Lyle PLC
25 July 2024
 

 

25 July 2024 - Tate & Lyle PLC

 

AGM STATEMENT AND TRADING UPDATE

 

Tate & Lyle PLC ('Tate & Lyle', 'the Group') will be holding its Annual General Meeting in London later today. In his address to shareholders, Chief Executive Nick Hampton will comment:

 

"We have made a good start to the new financial year with trading in line with our expectations. It's encouraging to see volume momentum across the business, and we continue to expect volume growth to accelerate as the 2025 financial year progresses. Planning for the integration of Tate & Lyle and CP Kelco is progressing well with both organisations excited about the opportunity to deliver significantly greater value for customers and the growth potential of the combined business. We look forward to the future with confidence."

 

Trading update for the three months ended 30 June 2024

· Group performance in line with our expectations:

- Food & Beverage Solutions volume, as anticipated, was ahead of the comparative period, with revenue lower reflecting the pass through of input cost deflation.

- Sucralose delivered good revenue growth.

- Group EBITDA ahead of the comparative period.

 

Acquisition of CP Kelco

· On 20 June 2024, Tate & Lyle entered into an agreement to acquire CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients for a total implied consideration of US$1.8 billion (approximately £1.4 billion).

· This acquisition significantly accelerates Tate & Lyle's strategy as a leading and differentiated speciality food and beverage solutions business, and the solutions partner of choice for customers. The combined business will be a leader in Mouthfeel solutions and will also provide a stronger customer offering across our Sweetening and Fortification platforms, and our four core categories. Further details of the acquisition can be found here.

· CP Kelco's financial performance in the first half of the 2024 calendar year has stabilised as anticipated, with volume well ahead of the comparative period.

· Following the announcement by the Financial Conduct Authority on 11 July 2024 that the new Listing Rules will come into effect on 29 July 2024, the requirement for a shareholder vote for significant transactions will no longer apply. We intend to comply with the new disclosure requirements for significant transactions that were announced ahead of the rule changes.

· Completion of the transaction remains conditional on receipt of regulatory approvals and other customary conditions. We continue to expect this will occur in the fourth quarter of the 2024 calendar year.

 

Progress on share buyback programme

· On 20 June 2024, we commenced a £215 million on-market share buyback programme to return the net cash proceeds from the sale of our remaining interest in Primient to shareholders. 

· As at the close of business on 24 July 2024, a total of 6.7 million shares have been purchased under this programme for a cost of £42 million and are being held as treasury shares.

 

Outlook for year ending 31 March 2025 is unchanged (for standalone Tate & Lyle, excluding CP Kelco)

· We continue to expect to deliver in constant currency:

- Revenue slightly lower than the prior year

- EBITDA growth of between 4% and 7%.

 

END

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

tate@fticonsulting.com

 

 

About Tate & Lyle:

 

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

We have more than 3,300 employees working in around 58 locations serving customers across

121 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2024, Tate & Lyle revenue from continuing operations totalled £1.65 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKQBBOBKDAOB
Date   Source Headline
11th Oct 20245:38 pmRNSTransaction in Own Shares
10th Oct 20245:36 pmRNSTransaction in Own Shares
9th Oct 20245:26 pmRNSTransaction in Own Shares
8th Oct 20245:32 pmRNSTransaction in Own Shares
7th Oct 20245:41 pmRNSTransaction in Own Shares
4th Oct 20245:58 pmRNSTransaction in Own Shares
3rd Oct 20245:34 pmRNSTransaction in Own Shares
3rd Oct 20247:00 amRNSInformation - combination Tate & Lyle / CP Kelco
2nd Oct 20245:47 pmRNSTransaction in Own Shares
1st Oct 20245:32 pmRNSTransaction in Own Shares
1st Oct 202412:00 pmRNSTotal Voting Rights
30th Sep 20245:25 pmRNSTransaction in Own Shares
27th Sep 20245:49 pmRNSTransaction in Own Shares
26th Sep 20245:33 pmRNSTransaction in Own Shares
25th Sep 20245:33 pmRNSTransaction in Own Shares
24th Sep 20243:00 pmRNSDirector/PDMR Shareholding
23rd Sep 20245:45 pmRNSTransaction in Own Shares
20th Sep 20245:40 pmRNSTransaction in Own Shares
19th Sep 20245:51 pmRNSTransaction in Own Shares
18th Sep 20245:31 pmRNSTransaction in Own Shares
17th Sep 20245:33 pmRNSTransaction in Own Shares
16th Sep 20245:40 pmRNSTransaction in Own Shares
13th Sep 20245:32 pmRNSTransaction in Own Shares
12th Sep 20245:41 pmRNSTransaction in Own Shares
11th Sep 20245:35 pmRNSTransaction in Own Shares
10th Sep 20245:42 pmRNSTransaction in Own Shares
9th Sep 20245:27 pmRNSTransaction in Own Shares
9th Sep 202411:00 amRNSHolding(s) in Company
6th Sep 20245:47 pmRNSTransaction in Own Shares
5th Sep 20245:47 pmRNSTransaction in Own Shares
5th Sep 20241:00 pmRNSHolding(s) in Company
4th Sep 20245:58 pmRNSTransaction in Own Shares
3rd Sep 20245:33 pmRNSTransaction in Own Shares
2nd Sep 20245:44 pmRNSTransaction in Own Shares
2nd Sep 20245:00 pmRNSTotal Voting Rights
30th Aug 20245:39 pmRNSTransaction in Own Shares
29th Aug 20245:26 pmRNSTransaction in Own Shares
28th Aug 20245:27 pmRNSTransaction in Own Shares
27th Aug 20245:34 pmRNSTransaction in Own Shares
23rd Aug 20245:49 pmRNSTransaction in Own Shares
22nd Aug 20245:45 pmRNSTransaction in Own Shares
22nd Aug 20244:00 pmRNSDirector/PDMR Shareholding
21st Aug 20246:00 pmRNSTransaction in Own Shares
20th Aug 20245:56 pmRNSTransaction in Own Shares
19th Aug 20245:44 pmRNSTransaction in Own Shares
16th Aug 20245:50 pmRNSTransaction in Own Shares
15th Aug 20245:57 pmRNSTransaction in Own Shares
14th Aug 20245:46 pmRNSTransaction in Own Shares
13th Aug 20245:54 pmRNSTransaction in Own Shares
13th Aug 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.